“This study shows that daratumumab added to KRd is a new standard of care for those patients who had previously been candidates for just KRd,” said C. Ola Landgren, M.D., Ph.D., director of the ...

Modern multiple myeloma treatment often involves complex combination therapies, which significantly impact daily life for patients and care partners. Modern multiple myeloma treatment often involves ...

Genetically modified immune cells can offer precious additional time to patients with advanced multiple myeloma. However, these therapies lose their impact as the molecules on cancer cells that immune ...

Today researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from the first ever clinical trial to show that a high fiber plant based dietary intervention may delay progression ...

-- Company to host a live webcast event with an expert panel of clinicians during ASH -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell ...

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated 20,030 new male cases diagnosed in 2025. Multiple myeloma is the ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Newly diagnosed multiple myeloma patients at Sylvester and other cancer centers are already routinely receiving the four-drug DKRd combination. "It has definitely changed my practice," said Sylvester ...